NASDAQ:SIBN SI-BONE (SIBN) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free sibn Stock Alerts $15.33 -0.21 (-1.35%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$15.17▼$15.7650-Day Range$14.20▼$17.8552-Week Range$13.96▼$29.51Volume449,563 shsAverage Volume436,706 shsMarket Capitalization$631.66 millionP/E RatioN/ADividend YieldN/APrice Target$27.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get SI-BONE alerts: Email Address SI-BONE MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside78.0% Upside$27.29 Price TargetShort InterestBearish6.84% of Shares Sold ShortDividend StrengthN/ASustainability-1.44Upright™ Environmental ScoreNews Sentiment0.40Based on 27 Articles This WeekInsider TradingSelling Shares$190,273 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.98) to ($0.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.28 out of 5 starsMedical Sector135th out of 921 stocksSurgical & Medical Instruments Industry19th out of 98 stocks 4.5 Analyst's Opinion Consensus RatingSI-BONE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSI-BONE has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about SI-BONE's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.84% of the outstanding shares of SI-BONE have been sold short.Short Interest Ratio / Days to CoverSI-BONE has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in SI-BONE has recently increased by 8.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSI-BONE does not currently pay a dividend.Dividend GrowthSI-BONE does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSI-BONE has received a 34.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cervical implants" product. See details.Environmental SustainabilityThe Environmental Impact score for SI-BONE is -1.44. Previous Next 2.4 News and Social Media Coverage News SentimentSI-BONE has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for SI-BONE this week, compared to 2 articles on an average week.Search Interest2 people have searched for SIBN on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SI-BONE insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $190,273.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of SI-BONE is held by insiders.Percentage Held by Institutions98.11% of the stock of SI-BONE is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about SI-BONE's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SI-BONE are expected to grow in the coming year, from ($0.98) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SI-BONE is -13.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SI-BONE is -13.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSI-BONE has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SI-BONE's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About SI-BONE Stock (NASDAQ:SIBN)SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Read More SIBN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SIBN Stock News HeadlinesMay 10, 2024 | americanbankingnews.comAnalysts Set SI-BONE, Inc. (NASDAQ:SIBN) Price Target at $27.29May 9, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For SI-BONE, Inc. (NASDAQ:SIBN) After Its First-Quarter ResultsMay 10, 2024 | Stansberry Research (Ad)Biggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."May 9, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates Buy Rating for SI-BONE (NASDAQ:SIBN)May 9, 2024 | americanbankingnews.comSI-BONE (NASDAQ:SIBN) PT Lowered to $25.00May 9, 2024 | americanbankingnews.comJMP Securities Reiterates "Market Outperform" Rating for SI-BONE (NASDAQ:SIBN)May 7, 2024 | markets.businessinsider.comSI-Bone’s Strong Financial Performance and Growth Potential Justify Buy RatingMay 7, 2024 | benzinga.comA Closer Look at 6 Analyst Recommendations For SI-BONEMay 10, 2024 | Stansberry Research (Ad)Biggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."May 7, 2024 | finance.yahoo.comSI-BONE, Inc. (NASDAQ:SIBN) Q1 2024 Earnings Call TranscriptMay 7, 2024 | globenewswire.comSI-BONE Expands Portfolio with the Launch of New Offering for the iFuse Bedrock Granite Implant System and Completes Inaugural Surgical ProceduresMay 7, 2024 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on SI-Bone (SIBN)May 7, 2024 | markets.businessinsider.comSI-Bone’s Strong Start and Revenue Growth Potential Affirm Buy RatingMay 7, 2024 | finance.yahoo.comSI-BONE Inc (SIBN) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ...May 6, 2024 | msn.comSIBN Stock Earnings: SI-BONE Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | globenewswire.comSI-BONE, Inc. Reports Financial Results for the First Quarter 2024May 5, 2024 | americanbankingnews.comSI-BONE (NASDAQ:SIBN) Sets New 1-Year Low at $14.07April 29, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on SI-Bone (SIBN)April 29, 2024 | globenewswire.comSI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024April 15, 2024 | globenewswire.comSI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024April 3, 2024 | markets.businessinsider.comSI-Bone’s Favorable Outlook and Buy Rating Amidst Stable Medical Coverage and Growth ProspectsMarch 28, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring SI-BONE Through Analyst InsightsMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for SI-Bone on Expansion and Market Growth StrategiesMarch 10, 2024 | finance.yahoo.comSIBN Apr 2024 2.500 putMarch 10, 2024 | finance.yahoo.comSIBN Jul 2024 10.000 putMarch 4, 2024 | globenewswire.comSI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024February 28, 2024 | finance.yahoo.comWhen Will SI-BONE, Inc. (NASDAQ:SIBN) Become Profitable?See More Headlines Receive SIBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today5/10/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:SIBN CUSIPN/A CIK1459839 Webwww.si-bone.com Phone(408) 207-0700FaxN/AEmployees344Year Founded2008Price Target and Rating Average Stock Price Target$27.29 High Stock Price Target$33.00 Low Stock Price Target$24.00 Potential Upside/Downside+76.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,340,000.00 Net Margins-31.20% Pretax Margin-31.20% Return on Equity-28.22% Return on Assets-20.53% Debt Debt-to-Equity Ratio0.21 Current Ratio9.01 Quick Ratio8.15 Sales & Book Value Annual Sales$144.05 million Price / Sales4.41 Cash FlowN/A Price / Cash FlowN/A Book Value$4.18 per share Price / Book3.69Miscellaneous Outstanding Shares41,204,000Free Float38,979,000Market Cap$635.78 million OptionableOptionable Beta1.24 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Laura A. Francis MBA (Age 57)CEO & Director Comp: $1.11MMr. Anshul Maheshwari (Age 44)Chief Financial Officer Comp: $614.25kMr. Anthony J. Recupero (Age 65)President of Commercial Operations Comp: $795.32kMr. Jeff BertoliniSenior Vice President of Operations & Information TechnologyDr. Scott A. Yerby (Age 56)Senior VP of Engineering & CTO Saqib IqbalDirector of FP&A and Investor RelationsMr. Michael A. Pisetsky (Age 46)Chief Business & Legal Affairs Officer Ms. Aimee EinsteinVice President of People & CultureDr. Daniel Joseph Cher (Age 59)Senior Vice President of Clinical & Regulatory Affairs Dr. W. Carlton Reckling (Age 62)Chief Medical Officer & VP of Medical Affairs More ExecutivesKey CompetitorsEmbectaNASDAQ:EMBCTreace Medical ConceptsNASDAQ:TMCICryoLifeNYSE:CRYAtrionNASDAQ:ATRIIradimedNASDAQ:IRMDView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 43,670 shares on 5/10/2024Ownership: 5.979%Russell Investments Group Ltd.Sold 109,080 shares on 5/8/2024Ownership: 0.008%Swiss National BankSold 3,400 shares on 5/7/2024Ownership: 0.175%Sei Investments Co.Sold 10,996 shares on 5/7/2024Ownership: 0.071%RiverPark Advisors LLCBought 8,206 shares on 5/3/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions SIBN Stock Analysis - Frequently Asked Questions Should I buy or sell SI-BONE stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SIBN shares. View SIBN analyst ratings or view top-rated stocks. What is SI-BONE's stock price target for 2024? 6 brokerages have issued 12 month target prices for SI-BONE's stock. Their SIBN share price targets range from $24.00 to $33.00. On average, they expect the company's share price to reach $27.29 in the next twelve months. This suggests a possible upside of 78.0% from the stock's current price. View analysts price targets for SIBN or view top-rated stocks among Wall Street analysts. How have SIBN shares performed in 2024? SI-BONE's stock was trading at $20.99 at the start of the year. Since then, SIBN stock has decreased by 27.0% and is now trading at $15.33. View the best growth stocks for 2024 here. When is SI-BONE's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our SIBN earnings forecast. How were SI-BONE's earnings last quarter? SI-BONE, Inc. (NASDAQ:SIBN) issued its earnings results on Monday, February, 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. The company had revenue of $38.86 million for the quarter, compared to analysts' expectations of $38.60 million. SI-BONE had a negative trailing twelve-month return on equity of 28.22% and a negative net margin of 31.20%. What ETF holds SI-BONE's stock? iShares U.S. Medical Devices ETF holds 246,858 shares of SIBN stock, representing 0.07% of its portfolio. What guidance has SI-BONE issued on next quarter's earnings? SI-BONE updated its FY 2024 earnings guidance on Monday, May, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $162.0 million-$165.0 million, compared to the consensus revenue estimate of $163.6 million. What is Jeffrey Dunn's approval rating as SI-BONE's CEO? 10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of SI-BONE own? Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), RTX (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX). When did SI-BONE IPO? SI-BONE (SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. Who are SI-BONE's major shareholders? SI-BONE's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.98%), Allspring Global Investments Holdings LLC (0.41%), BNP Paribas Financial Markets (0.21%), Swiss National Bank (0.17%), Sei Investments Co. (0.07%) and Diversified Trust Co (0.05%). Insiders that own company stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky, Michael A Pisetsky, Mika Nishimura and Timothy E Davis Jr. View institutional ownership trends. How do I buy shares of SI-BONE? Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does SI-BONE have any subsidiaries? The following companies are subsidiares of SI-BONE: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.Read More This page (NASDAQ:SIBN) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SI-BONE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
